BIOMAT Database Logo BIOMAT Database Logo

Role of factor VIII C2 domain in factor VIII binding to factor Xa. 1999

K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Department of Pediatrics, Nara Medical University, 840 Shijo-cho Kashihara City, Nara 634, Japan.

Factor VIII (FVIII) is activated by proteolytic cleavages with thrombin and factor Xa (FXa) in the intrinsic blood coagulation pathway. The anti-C2 monoclonal antibody ESH8, which recognizes residues 2248-2285 and does not inhibit FVIII binding to von Willebrand factor or phospholipid, inhibited FVIII activation by FXa in a clotting assay. Furthermore, analysis by SDS-polyacrylamide gel electrophoresis showed that ESH8 inhibited FXa cleavage in the presence or absence of phospholipid. The light chain (LCh) fragments (both 80 and 72 kDa) and the recombinant C2 domain dose-dependently bound to immobilized anhydro-FXa, a catalytically inactive derivative of FXa in which dehydroalanine replaces the active-site serine. The affinity (K(d)) values for the 80- and 72-kDa LCh fragments and the C2 domain were 55, 51, and 560 nM, respectively. The heavy chain of FVIII did not bind to anhydro-FXa. Similarly, competitive assays using overlapping synthetic peptides corresponding to ESH8 epitopes (residues 2248-2285) demonstrated that a peptide designated EP-2 (residues 2253-2270; TSMYVKEFLISSSQDGHQ) inhibited the binding of the C2 domain or the 72-kDa LCh to anhydro-FXa by more than 95 and 84%, respectively. Our results provide the first evidence for a direct role of the C2 domain in the association between FVIII and FXa.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002846 Chromatography, Affinity A chromatographic technique that utilizes the ability of biological molecules, often ANTIBODIES, to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Bioaffinity,Immunochromatography,Affinity Chromatography,Bioaffinity Chromatography
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
A role for the C2 domain of factor VIII in binding to von Willebrand factor.
April 1994, The Journal of biological chemistry,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.
June 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Membrane-binding properties of the Factor VIII C2 domain.
April 2011, The Biochemical journal,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Relating structure to function: the role of the C2 domain in Factor VIII.
September 2000, Current opinion in drug discovery & development,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.
May 1990, Blood,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Functional mapping of factor VIII C2 domain.
July 2011, Thrombosis and haemostasis,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
The preparation and phospholipid binding property of the C2 domain of human factor VIII.
May 2003, Thrombosis and haemostasis,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
November 1995, British journal of haematology,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain.
October 2006, Journal of thrombosis and haemostasis : JTH,
K Nogami, and M Shima, and K Hosokawa, and T Suzuki, and T Koide, and E L Saenko, and D Scandella, and M Shibata, and S Kamisue, and I Tanaka, and A Yoshioka
Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.
May 2003, Thrombosis and haemostasis,
Copied contents to your clipboard!